Home / ACCCBuzz Blog / Full Story

ACCC Asks Senate Leaders to Include Clinical Trial Diversity Provisions in PDUFA Reauthorization


June 8, 2022

In a letter to Senate Health, Education, Labor & Pensions (HELP) Committee leadership, ACCC and 71 other patient advocacy organizations urge the Committee to include House-passed clinical trials diversity provisions in the Senate version of the Prescription Drug User Fee Act (PDUFA) reauthorization package.
Read the Letter


«« Previous
ACCC Submits Comments to FDA on Draft Guidance to Increase Diversity in Clinical Trials
Next »»
ACCC Urges Congress to Pass Legislation Improving Clinical Trial Diversity

Categories

We welcome you to share our blog content. We want to connect people with the information they need. We just ask that you link back to the original post and refrain from editing the text. Any questions? Email CJ Ike, Content Manager.

To receive a weekly digest of ACCCBuzz blog posts each Friday, please sign up in the box to the left.

 

More Blog Posts

Related Content